Patients with nasopharyngeal carcinoma or breast cancer have been enrolled in a phase I clinical trial, which investigated the safety and tolerability of epithelial cell adhesion molecule (EpCAM)- specific CAR-T cells, in terms of treatment-related AEs and maximum tolerated dose (MTD). This evidence concerns the gene EPCAM and breast carcinoma.